.jpg)
1 hour ago
2
Article content
SNOQUALMIE, Wash., March 25, 2026 (GLOBE NEWSWIRE) — InhaleH₂, a precision hydrogen inhalation technology developed by Alex Tarnava, inventor of the open-cup hydrogen water tablets, and well-known H2 researcher Dr. Tyler LeBaron, MSc, Ph.D., has received recognition under Canada’s Scientific Research and Experimental Development (SR&ED) program for its breakthrough work in controlled hydrogen gas delivery.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
The SR&ED program is the Canadian government’s primary incentive for innovation, supporting projects that demonstrate meaningful scientific or technological advancement through systematic experimentation. Recognition under the program signals that a company’s work addresses unresolved technical challenges and advances the state of knowledge in its field.
Article content
Article content
Article content
InhaleH₂ was recognized for solving a longstanding problem in hydrogen therapy: how to safely and consistently deliver precise concentrations of hydrogen gas in real time with human breathing.
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
“This was the result of over seven years of focused research and development,” said Dr. Tyler LeBaron, co-founder of the InhaleH₂. “We were tackling a problem that hadn’t been solved—how to deliver hydrogen in a way that is precise, safe, and aligned with real human breathing patterns.”
Article content
During his PhD research, Dr. Tyler LeBaron utilized hydrogen gas delivered from pre-mixed tanks at concentrations below established flammability thresholds, enabling precise control in experimental settings. However, translating these conditions into practical, real-world applications proved challenging. Existing industry devices were unable to reliably achieve biologically relevant hydrogen concentrations while maintaining safety standards, nor could they adapt to variability in individual breathing patterns.
Article content
To address these challenges, the InhaleH₂ team engineered a delivery system designed to maintain a stable hydrogen concentration throughout each inhalation. Developing this approach required overcoming multiple scientific uncertainties related to gas kinetics, flow dynamics, and human breathing variability. Through hypothesis-driven experimentation and iterative development the resulting innovation is the subject of internationally filed patents and enables precise, real-time control of hydrogen concentrations within established safety limits, advancing the company’s mission to support clinical research while making hydrogen therapy more accessible to early adopters
Article content
Article content
The result is InhaleH₂, a precision hydrogen inhalation platform that delivers a consistent fraction of hydrogen gas (FiH₂) with every breath. The system allows users to target concentrations between 0.5% and 4.0%, while built-in safety mechanisms ensure levels remain within established thresholds.
Article content
The device is designed to replicate delivery conditions used in clinical research, supporting more consistent application of hydrogen therapy protocols.
Article content
SR&ED recognition places InhaleH₂ among a select group of Canadian innovations that have demonstrated true technological advancement, reinforcing the company’s position at the forefront of hydrogen-based therapeutic delivery systems.
Article content
About InhaleH₂
Article content
InhaleH₂ is a precision health technology company focused on advancing hydrogen inhalation therapy through engineering innovation. Founded by Alex Tarnava and Dr. Tyler LeBaron, the company has spent over seven years developing a precision system capable of delivering safe, consistent hydrogen concentrations aligned with real-time human breathing.
Article content
The InhaleH₂ platform is designed to replicate clinical research delivery methods while ensuring safety, reliability, and ease of use, enabling a more precise application of hydrogen therapy across both research and consumer settings. For inquiries about purchasing the InhaleH₂ hydrogen inhalation therapy machine for home, clinic, hospital, research, or medical spa use please visit www.inhaleh2.com or call 855-291-2422.
Article content
Article content
Article content
Article content
Article content
Article content
English (US)